Prognostic Significance of CYFRA21-1, CEA and Hemoglobin in Patients with Esophageal Squamous Cancer Undergoing Concurrent Chemoradiotherapy |
Zhang, Hai-Qin
(Department of Radiation Oncology, Shandong Cancer Hospital)
Wang, Ren-Ben (Department of Radiation Oncology, Shandong Cancer Hospital) Yan, Hong-Jiang (Department of Radiation Oncology, Shandong Cancer Hospital) Zhao, Wei (Department of Radiation Oncology, Shandong Cancer Hospital) Zhu, Kun-Li (Department of Radiation Oncology, Shandong Cancer Hospital) Jiang, Shu-Mei (Department of Radiation Oncology, Shandong Cancer Hospital) Hu, Xi-Gang (Department of Radiation Oncology, Shandong Cancer Hospital) Yu, Jin-Ming (Department of Radiation Oncology, Shandong Cancer Hospital) |
1 | Rades D, Lang S, Schild SE, et al (2006). Prognostic value of haemoglobin levels during concurrent radio-chemotherapy in the treatment of oesophageal cancer. Clin Oncol, 18, 139-44. DOI |
2 | Rades D, Schild SE, Bahrehmand R, et al (2005). Prognostic factors in the nonsurgical treatment of esophageal carcinoma with radiotherapy or radiochemotherapy: the importance of pretreatment hemoglobin levels. Cancer, 103, 1740-6. DOI |
3 | Rice TW, Zuccaro G Jr, Adelstein DJ, et al (1998). Esophageal carcinoma: depth of tumor invasion is predictive of regional lymph node status. Ann Thorac Surg, 65, 787-92. DOI |
4 | Shimada H, Nabeya Y, Okazumi S, et al (2003). Prognostic significance of CYFRA 21-1 in patients with esophageal squamous cell carcinoma. J Am Coll Surg, 196, 573-8. DOI |
5 | Tachibana M, Kinugasa S, Yoshimura H, et al (2005). Clinical outcomes of extended esophagectomy with three-field lymph node dissection for esophageal squamous cell carcinoma. Am J Surg, 189, 98-109. DOI |
6 | Tepper J, Krasna MJ, Niedzwiecki D, et al (2008). Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol, 26, 1086-92. DOI |
7 | Urba SG, Orringer MB, Turrisi A, et al (2001). Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol, 19, 305-13. DOI |
8 | Wiggers T, Arends JW, Verstijnen C, et al (1986). Prognostic significance of CEA immunoreactivity patterns in large bowel carcinoma tissue. Br J Cancer, 54, 409-14. DOI |
9 | Yamamoto K, Oka M, Hayashi H, et al (1997). CYFRA 21-1 is a useful marker for esophageal squamous cell carcinoma. Cancer, 79, 1647-55. DOI |
10 | Yi Y, Li B, Wang Z, Sun H, et al (2009). CYFRA21-1 and CEA are useful markers for predicting the sensitivity to chemoradiotherapy of esophageal squamous cell carcinoma. Biomarkers, 14, 480-5. DOI |
11 | Brockmann JG, St Nottberg H, Glodny B, et al (2000). CYFRA 21-1 serum analysis in patients with esophageal cancer. Clin Cancer Res, 6, 4249-52. |
12 | Hamada Y, Yamamura M, Hioki K, et al (1985). Immunohistochemical study of carcinoembryonic antigen in patients with colorectal cancer. Cancer, 55, 136-41. DOI |
13 | Hu Y, Zheng B, Rong TH, Fu JH, et al (2010). Prognostic analysis of the patients with stageIII esophageal squamous cell carcinoma after radical esophagectomy. Chin J Cancer, 29, 178-83. DOI |
14 | Kawashima M, Ikeda H, Yorozu A, et al (1998). Clinical features of esophageal cancer in the octogenarian treated by definitive radiotherapy: a multi-institutional retrospective survey. Jpn J Clin Oncol, 28, 301-7. DOI |
15 | Midiri G, Amanti C, Benedetti M, et al (1985). CEA tissue staining in colorectal cancer patients. A way to improve the usefulness of serial serum CEA evaluation. Cancer, 55, 2624-9. DOI |
16 | Kijima H, Oshiba G, Kenmochi T, et al (2000). Stomal CEA immunoreactivity is correlated with lymphatic invasion of human esophageal carcinoma. Int J Oncol, 16, 677-82. |
17 | Kunisaki C, Akiyama H, Nomura M, et al (2005). Developing an appropriate staging system for esophageal carcinoma. J Am Coll Surg, 201, 884-90. DOI |
18 | Medical Research Council Oesophageal Cancer Working Party. (2002). Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet, 359, 1727-33. DOI |
19 | Nakamura T, Ide H, Eguchi R, et al (1998). CYFRA 21-1 as a tumor marker for squamous cell carcinoma of the esophagus. Dis Esophagus, 11, 35-9. DOI |
20 | Park JW, Kim JH, Choi EK, et al (2011). Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys, 81, 691-7. DOI |
21 | Bedenne L, Michel P, Bouche O, et al (2007). Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol, 25,1160-8. DOI |